Seattle Genetics seattlegenetics.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics develops antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics develops antibody-drug conjugates (ADCs), a technology designed to harne...Show all

Company (IPO / Went public)

Phone: 425-527-4000

Fax: (425) 527-4001

21823 - 30th Drive S.E.
Building 3
Bothell, 98021
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Seattle Genetics $128.1M Jul 8, 2003
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Seattle Genetics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 14 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Oscient Pharmaceuticals

Waltham, Massachusetts, United States
IPO / Went publicOscient Pharmaceuticals develops anti-infective therapeuticsLogin to see details

gera Therapeutics

Canada
AcquiredAegera Therapeutics, located in Montreal, Canada, is a business unit of Pharmascience focused on developing targeted therapeutics to address major unmet medical needs. Aegera focuses on preclinical and early-stage clinical development through integration of "in-house" medicinal chemistry, biochemistry, cell biology, pharmacokinetics and in vivo pharmacology/efficacy. Aegera has two oncology programs in clinical development. Aegera is also dedicated to identifying novel development candidates bas...Show allLogin to see details
See all 14 competitors